ArticleMedical oncology (Northwood, London, England)2026
Diosmetin overcomes resistance to cisplatin in ovarian cancer by suppressing the MAPK signaling pathway.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cisplatin (DDP) is a widely used chemotherapeutic agent for ovarian cancer (OC) therapy. However, the adverse effects and frequent resistance to DDP make its therapeutic efficacy suboptimal. Combination treatment with an agent capable of overcoming DDP resistance may be a promising solution. Here, we conducted a drug library screen for agents that increase DDP efficiency in a trained DDP-resistant OC cell line (SKOV3/DDP). Diosmetin (Dio), a natural flavonoid abundant in olive leaves and citrus fruits, was identified to synergize with DDP to reduce OC cell growth through apoptosis both in vitro and in vivo, as evidenced by increased expression of the proapoptotic proteins Cleaved-Caspase3 and Cleaved-PARP, as well as decreased expression of the antiapoptotic protein BCL-2 in SKOV3/DDP cells. Mechanistically, compared with Dio or DDP treatment alone, combined Dio and DDP treatment suppressed the MAPK signaling pathway, represented by reduced phosphorylation of JNK, ERK, and P38. These findings demonstrated that Dio potentiates the anticancer effects of DDP both in vitro and in vivo, indicating that Dio is a promising adjuvant for OC treatment.
Indexed as
Identifiers
42008005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.